Latest News
04-11-18 Zogenix to Participate in LEERINK Partners CNS Day 03-06-18 Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results 02-27-18 Zogenix to Release Fourth Quarter and Full-Year 2017 Financial Results and Host Conference Call and Webcast on March 6 more »Spotlight on Clinical Studies
The Zogenix study entitled "A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Audlts with Lennox-Gastaut Syndrome" is being conducted for patients with Lennox-Gastaut syndrome who are not adequately controlled on their current seizure medication. For more information, please visit www.clinicaltrials.gov listing (NCT03355209).
more »Scientific Publications
- ZX008 (Fenfluramine HCl Oral Solution) in Dravet Syndrome: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
- Low-Dose Fenfluramine Provides Significant and Long-Term Seizure Reduction in Dravet Syndrome: Update and Follow-Up of the Prospective Study
- A Pilot, Open-Label Study of the Effectiveness and Tolerability of Low-Dose Fenfluramine (ZX008) in Lennox-Gastaut Syndrome: Findings From a Long-Term Extension